# Pharmacokinetic Study of a Novel Cannabidiol (CBD) Formulation in Healthy Volunteers

> **NCT07186283** · PHASE1 · COMPLETED · sponsor: **NW PharmaTech Ltd** · enrollment: 14 (actual)

## Conditions studied

- PK in Healthy Volunteers

## Interventions

- **DRUG:** CBD soft-gel capsules 600 mg
- **DRUG:** CBD soft-gel capsules 900 mg
- **DRUG:** Epidyolex

## Key facts

- **NCT ID:** NCT07186283
- **Lead sponsor:** NW PharmaTech Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-22
- **Primary completion:** 2025-12-10
- **Final completion:** 2025-12-10
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07186283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07186283, "Pharmacokinetic Study of a Novel Cannabidiol (CBD) Formulation in Healthy Volunteers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07186283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*